Z-VDVAD-FMK: Irreversible Caspase-2 Inhibitor for Apoptosis Research

Executive Summary: Z-VDVAD-FMK (benzyloxycarbonyl-Val-Asp(OMe)-Val-Ala-Asp(OMe)-fluoromethyl ketone) is an irreversible caspase-2 inhibitor, covalently binding to the enzyme's active site and preventing proteolytic activity [APExBIO]. Its action inhibits mitochondrial cytochrome c release, a key step in intrinsic apoptosis [ProteaseInhibitorCocktail]. The inhibitor is also active against caspases-3 and -7, supporting broad utility in cell death research. Z-VDVAD-FMK is highly soluble in DMSO (≥34.8 mg/mL) and stable for short-term storage at -20°C. It is widely used for apoptosis assays in cancer and neurodegenerative disease models (Padia et al., 2025).

Biological Rationale

Caspase-2 is a cysteine protease with a pivotal role in apoptosis initiation. Apoptosis, or programmed cell death, is essential for tissue homeostasis and development (Padia et al., 2025). Dysregulation of apoptotic pathways is implicated in cancer, neurodegeneration, and immunological disorders. Caspase-2 activation can trigger mitochondrial outer membrane permeabilization (MOMP), leading to cytochrome c release and downstream caspase cascade activation. Caspase-2 also intersects with pyroptosis and other cell death programs, making it a valuable research target [Z-VDVAD-FMK: Next-Gen Research]. Z-VDVAD-FMK enables selective inhibition of caspase-2 and its downstream effects.

Mechanism of Action of Z-VDVAD-FMK

Z-VDVAD-FMK is a synthetic peptidyl fluoromethyl ketone. It irreversibly inhibits caspase-2 by covalently modifying the active site cysteine residue. This prevents substrate cleavage and downstream signaling. The inhibitor also displays cross-reactivity with caspase-3 and caspase-7 at higher concentrations, but retains highest affinity for caspase-2 (APExBIO). By blocking caspase-2, Z-VDVAD-FMK arrests mitochondrial cytochrome c release and downstream events such as PARP (poly(ADP-ribose) polymerase) cleavage. This mechanism enables researchers to dissect the role of caspase-2 in apoptotic and non-apoptotic cell death pathways [ProteaseInhibitorCocktail].

Evidence & Benchmarks

• Z-VDVAD-FMK inhibits caspase-2 activity irreversibly in cell-free and cellular assays (https://www.apexbt.com/z-vdvad-fmk.html).
• In endothelial cell models, Z-VDVAD-FMK reduces oxyhemoglobin-induced caspase-2 and caspase-3 activity, DNA fragmentation, and PARP cleavage (https://doi.org/10.1038/s41419-025-07867-8).
• The compound blocks mitochondrial cytochrome c release in apoptosis models, enabling mechanistic dissection of intrinsic cell death pathways (https://proteaseinhibitorcocktail.com/index.php?g=Wap&m=Article&a=detail&id=10924).
• Z-VDVAD-FMK demonstrates cross-reactivity with caspase-3 and caspase-7 at elevated concentrations, providing a tool for broader caspase pathway studies (https://z-vdvad-fmk.com/index.php?g=Wap&m=Article&a=detail&id=3).
• Solubility benchmarks: ≥34.8 mg/mL in DMSO, insoluble in ethanol and water; stock solutions >10 mM are stable short-term at -20°C (https://www.apexbt.com/z-vdvad-fmk.html).

For additional protocol guidance and reproducibility benchmarks, see the scenario-driven guide "Z-VDVAD-FMK (SKU A1922): Practical Solutions for Caspase-...", which this article extends by providing updated evidence from recent primary literature and highlighting cross-reactivity profiles.

Applications, Limits & Misconceptions

Z-VDVAD-FMK is used primarily in apoptosis research, including cancer, neurodegenerative, and immunological disease models. It is suitable for mechanistic studies of caspase signaling, mitochondrial-mediated apoptosis, and PARP cleavage inhibition. The compound supports apoptosis assays in cell lines such as Jurkat T-lymphocytes (typical use: 25–100 μM, 1–22 hours) [BCA-Protein guide]. This expands on previous mechanistic reviews by emphasizing workflow integration and optimizing assay conditions.

Common Pitfalls or Misconceptions

• Not selective for caspase-2 at high concentrations: Cross-reactivity with caspase-3 and -7 increases at ≥100 μM.
• Not effective in ethanol or water: Z-VDVAD-FMK is insoluble in these solvents and must be prepared in DMSO for biological use.
• Not stable for long-term storage at room temperature: Stock solutions should be stored at -20°C and used promptly after thawing.
• Not suitable for in vivo applications without further pharmacokinetic validation: Current evidence is limited to cell-based and cell-free assays.
• Not a pan-caspase inhibitor: Z-VDVAD-FMK does not broadly inhibit all caspases; its highest selectivity is for caspase-2.

Workflow Integration & Parameters

For experimental use, dissolve Z-VDVAD-FMK at ≥34.8 mg/mL in DMSO. Prepare stock solutions >10 mM; warming and ultrasonic treatment may enhance solubility. Use immediately or store aliquots at -20°C for short-term. Typical cell culture conditions: treat Jurkat T-lymphocytes or other cell lines with 25–100 μM for 1–22 hours. Avoid repeated freeze-thaw cycles. The product is supplied at 98% purity and should be handled with standard laboratory precautions [APExBIO]. For detailed protocol adaptation, see "Z-VDVAD-FMK (SKU A1922): Enhancing Apoptosis & Caspase As...", which this article updates by providing latest concentration parameters and storage recommendations.

Conclusion & Outlook

Z-VDVAD-FMK (SKU A1922, supplied by APExBIO) is a validated, high-purity irreversible caspase-2 inhibitor for apoptosis and caspase pathway research. Its ability to block mitochondrial cytochrome c release and PARP cleavage makes it a critical tool for dissecting cell death mechanisms in cancer and neurodegenerative disease models. Ongoing research continues to clarify the role of caspase-2 in non-apoptotic cell death, expanding future applications. For ordering and further specifications, consult the official Z-VDVAD-FMK product page.